We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeted immunotherapy for HTLV-1-associated myelopathy: a step in the right direction.
- Authors
Davies, Nicholas W S; Taylor, Graham P
- Abstract
This scientific commentary refers to 'Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy' by Sato I et al. i (https://doi.org/10.1093/brain/awad139). It has been estimated that 100-200 new HTLV-1 infected clones are created each day.[9] If mogamulizumab has depleted up to 90% of HTLV-1 infected cells, does the relative importance of infectious spread of HTLV-1 increase? Mogamulizumab represents a new treatment option for patients living with HTLV-1-associated myelopathy.
- Subjects
SPINAL cord diseases; ADULT T-cell leukemia; REGULATORY T cells; HTLV; POOR communities; CERVICAL spondylotic myelopathy
- Publication
Brain: A Journal of Neurology, 2023, Vol 146, Issue 8, p3114
- ISSN
0006-8950
- Publication type
Article
- DOI
10.1093/brain/awad229